Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response

Leuk Lymphoma. 2018 Aug;59(8):1994-1997. doi: 10.1080/10428194.2017.1406087. Epub 2017 Dec 3.

Authors

Magdalena M Gerlach¹, Pontus Lundberg², Joerg Halter², Christian Arranto², Friedel Wenzel³, Stefan Dirnhofer¹, Alexandar Tzankov¹

Affiliations

¹ a Institute of Pathology , University Hospital Basel , Basel , Switzerland.
² b Department for Hematology , University Hospital Basel , Basel , Switzerland.
³ c Institute of Medical Genetics , University Hospital Basel , Basel , Switzerland.

PMID: 29199511
DOI: 10.1080/10428194.2017.1406087

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
DNA-Binding Proteins / genetics*
Dioxygenases
Humans
Janus Kinase 2 / genetics*
Male
Mutation*
Myeloproliferative Disorders / drug therapy
Myeloproliferative Disorders / genetics*
Myeloproliferative Disorders / pathology
Nitriles
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins / genetics*
Pyrazoles / therapeutic use
Pyrimidines
Receptors, Colony-Stimulating Factor / genetics*
Splicing Factor U2AF / genetics*

Substances

CSF3R protein, human
DNA-Binding Proteins
Nitriles
Protein Kinase Inhibitors
Proto-Oncogene Proteins
Pyrazoles
Pyrimidines
Receptors, Colony-Stimulating Factor
Splicing Factor U2AF
U2AF1 protein, human
ruxolitinib
Dioxygenases
TET2 protein, human
JAK2 protein, human
Janus Kinase 2